ArticleFrontiers in oncology2022

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.

Lucheng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.